Technology | March 10, 2011

PET Fludeoxyglucose F18 Injection Gains FDA Clearance


March 10, 2011 – The U.S. Food and Drug Administration (FDA) has granted an abbreviated new drug application (ANDA) for a fludeoxyglucose (FDG) F18 injection. Siemens PETNet Solutions is the first commercial manufacturer and distributor to achieve approval of an ANDA for F18 FDG.

F18 is used in oncology for the assessment of abnormal glucose metabolism to assist in the evaluation of known or suspected abnormalities. In cardiology, it is used together with myocardial perfusion imaging to assist in identifying left ventricular myocardium with residual glucose metabolism. It can also be used to identify reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction. In neurology, F18 is used for the identification of regions of abnormal glucose metabolism associated with epileptic seizure foci.

Because radiation-emitting products may increase the risk for cancer, especially in pediatric patients, the smallest dose necessary for imaging should be used. In the oncology and neurology settings, suboptimal imaging may occur in patients with inadequately regulated blood glucose levels. Medical therapy and lab testing may be used to assure at least two days of normal levels prior to FDG administration. Hypersensitivity reactions with itching, edema and rash have been reported, therefore emergency resuscitation equipment and personnel should be available.

For more information: www.siemens.com/healthcare


Additional Content

News | PET Imaging

Nov. 17, 2025 — GE HealthCare has announced that Cardiovascular Associates of America (CVAUSA) plans to broaden its ...

Home November 17, 2025
Home
News | PET Imaging

Sept. 18, 2025 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI), American Society of Nuclear Cardiology ...

Home September 22, 2025
Home
News | PET Imaging

Sept. 8, 2025 — GE HealthCare recently announced a Distribution and Services Agreement (DSA) with CardioNavix, a part of ...

Home September 08, 2025
Home
News | PET Imaging

July 21, 2025 — Long COVID patients with abnormal cardiopulmonary PET/MR findings may be more likely to develop heart ...

Home July 22, 2025
Home
News | PET Imaging

Feb. 25, 2025— GE HealthCare has delivered the first patient doses of Flyrcado (flurpiridaz F 18) injection, a unit dose ...

Home March 03, 2025
Home
Subscribe Now